Analysts: Biondvax Pharmaceuticals Ltd (BNDX.TA)

Consensus Recommendations

No consensus recommendations data available;

Analyst Recommendations and Revisions

No analyst recommendations and revisions data available;

Consensus Estimates Analysis

No consensus analysis data available.

Historical Surprises

No historical surprise data available.

Consensus Estimates Trend

No consensus estimates data available.

Estimates Revisions Summary

No estimates revision data available.

Earnings vs. Estimates

No consensus analysis data available.

» More Financials

Biondvax Pharmaceuticals Ltd News

» More BNDX.TA News

Analyst Research Reports

Report Title	Price
Biondvax Pharmaceuticals Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. Provider: Reuters Investment Profile	$20.00 Buy
BiondVax Pharmaceuticals Ltd. (BNDX) - Financial Analysis Review Provider: GlobalData	$125.00 Buy
BiondVax Pharmaceuticals Ltd. (BNDX) - Financial Analysis Review Provider: GlobalData	$125.00 Buy
BiondVax Pharmaceuticals Ltd. (BNDX) - Financial Analysis Review Provider: GlobalData	$125.00 Buy
BiondVax Pharmaceuticals Ltd. (BNDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Provider: GlobalData	$250.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Edition:

U.S.
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.